Lucky No. 13: Kardigan Raises $400m In Its Public Market Debut
Kardigan, after raising $554m in venture capital last year, grossed $400m in the 13th biopharma IPO in the US in 2026. The proceeds will fund ongoing Phase IIb trials in cardiovascular diseases.
Scrip - June 19, 2026

A Trio Of New Financings May Signal An Improving Early-Stage VC Market
Triveni raised $65m, while Vedana and Spot came out of stealth with $46m and $40m, respectively, potentially signaling that earlier-stage biotechs are gaining ground with investors.
Scrip - June 19, 2026

Spot Bio Launches With $40m And First Non-Viral Delivery of Full-Length Dystrophin
The US headquartered firm is using a China-based clinical trial to pioneer its extracellular vesicle in the muscle-wasting disease, Duchenne muscular dystrophy.
Scrip - June 19, 2026

Message Received: European Parliament Backs Industry Push For UWWTD Pause
At Medicines for Europe’s annual conference in Athens last week, industry leaders called for a halt on implementing the controversial Urban Waste Water Treatment Directive. Yesterday, the European Parliament voted in favor of a pause. And multiple EU-level legal cases are also pursuing challenges.
Generics Bulletin - June 19, 2026

Deal Watch: Merck Tasks Protillion With Multi-Target AI-Driven Drug Discovery
Plus deals involving Lonza/Antharis, HMNC/MEDICE, Adial/Azora, Guard Therapeutics/Disruptive Pharma, GSK/Engitix and more.
Scrip - June 19, 2026

Enanta Eyes $2bn High-Risk RSV Market
The company has held a successful end-of-Phase II meeting with the US FDA to advance zelicapavir into late-stage trials.
Scrip - June 19, 2026

Stroke Therapy Using Robotic Exoskeletons Linking Therapist And Patient Shows Promise
A new study from Northwestern University and Shirley Ryan AbilityLab shows early promise for a new rehabilitation system that virtually connects therapists and stroke patients through robotic exoskeletons.
Medtech Insight - June 19, 2026

Diagnostics and Surveillance Gaps Drive UK’s New Outbreak-Response Network
The Multi-Hazard Research Network merges social science with epidemiology to tackle cascading hazards — showing why treating disease alone is never enough.
Medtech Insight - June 19, 2026

Denali Monetizes Rare Pediatric Disease Voucher In $195m Deal After Avlayah FDA Nod
The voucher sale gives Denali additional financial flexibility as it seeks to advance therapies spanning lysosomal storage disorders and neurodegenerative diseases.
Scrip - June 19, 2026

First Xofluza Generic Approved In The US
The US FDA approved the first single-dose generic treatment for influenza, a rival to Genentech’s Xofluza from Norwich Pharmaceuticals, in time for the 2026-2027 flu season.
Generics Bulletin - June 19, 2026

Aurobindo Gets FTC Go-Ahead For Lannett Takeover – But With Strings Attached
Aurobindo expects to complete its pending acquisition of Lannett by the end of the month after the US Federal Trade Commission approved the deal – conditional on four product divestments.
Generics Bulletin - June 19, 2026

Brazil Builds Biosimilar Momentum With Eylea, Stelara Rivals
Brazil’s Anvisa has approved Celltrion’s Eydenzelt and SteinCares’ Uztok, adding a second Eylea biosimilar and another Stelara rival as the country’s biosimilar market gains policy and regulatory momentum.
Generics Bulletin - June 19, 2026

The Drug Development Sector Is Failing Patients – And It Is Time We Asked Why
Most late-stage drug failures stem from flawed development strategy, not bad science. Reversing biopharma's capital drought demands operational and commercial rethinking, not better technology.
In Vivo - June 19, 2026

A Milestone And A Warning: EU’s First JCA Exposes Gaps Before 2028 Rare-Disease Deadline
The first ever EU-level joint clinical assessment report marks a major milestone for the EU market access environment.
In Vivo - June 19, 2026

Teijin Pharma Divesting Products To Tighten Rare Disease Focus
Teijin Pharma is divesting seven products as it pivots towards a rare disease-focused strategy anchored by recently approved hypoparathyroidism therapeutic Yorvipath.
Scrip - June 19, 2026

Vietnam Mandates Free Annual Health Screening For All Citizens From 2026
A new prime ministerial directive commits Vietnam to at least one free check-up or screening per citizen each year, the latest step in a prevention-first agenda reshaping the country's consumer health environment.
HBW Insight - June 19, 2026